title: Efficacy of bupropion in the indigenous Maori population in New Zealand.
abstract: BACKGROUND
  Smoking rates are high in indigenous populations and contribute to their poor health. In New Zealand the indigenous Maori population has a high rate of smoking, with around 50% of adults being smokers compared with 20% of the adult European population. A study was undertaken to determine whether bupropion is effective in the treatment of smoking cessation in the indigenous Maori population in New Zealand.
  
  
  METHODS
  A randomised, placebo controlled, double blind, parallel group study was performed in 134 Maori smokers aged 16-70 years who smoked more than 10 cigarettes per day. The main outcome measures were continued abstinence from smoking at 3 and 12 months.
  
  
  RESULTS
  At each time point continued abstinence was better for the subjects allocated to bupropion, with a risk ratio for abstinence over all time points of 2.44 (95% CI 1.22 to 4.88). The rates of continued abstinence in the bupropion and placebo groups at 3 months were 44.3% and 17.4%, respectively, with a risk ratio of 2.54 (95% CI 1.30 to 5.00). The corresponding figures at 12 months were 21.6% and 10.9%, respectively, with a risk ratio of 1.99 (95% CI 0.79 to 5.00).
  
  
  CONCLUSIONS
  Bupropion is an effective treatment for smoking cessation in the indigenous Maori population in New Zealand.
authors.affiliation: P3 Research, Bowen Hospital, Crofton Downs, Wellington, New Zealand. shaun@p3research.co.nz
authors.forename: S
authors.initials: S
authors.lastname: Holt
authors.forename: C
authors.initials: C
authors.lastname: Timu-Parata
authors.forename: S
authors.initials: S
authors.lastname: Ryder-Lewis
authors.forename: M
authors.initials: M
authors.lastname: Weatherall
authors.forename: R
authors.initials: R
authors.lastname: Beasley
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016642:Bupropion / Q000627:therapeutic use*; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009520:New Zealand / Q000208:ethnology; D012307:Risk Factors; D012907:Smoking / Q000208:ethnology; D016540:Smoking Cessation / Q000379:methods*; D000074606:Smoking Prevention; D016896:Treatment Outcome
chemical_list: D018765:Dopamine Uptake Inhibitors; D016642:Bupropion